People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year.
